Seattle startup Circulate Health raises $12M for pricey ‘blood-cleaning' longevity service
Circulate Health, a Seattle health longevity startup, today announced $12 million in seed funding.
The company is partnering with two-dozen clinics in eight states to provide a blood-cleaning service for patients in pursuit of longer, healthier lives. It recently published a study of 42 adults showing potential benefits following repeated treatments.
Circulate is deploying machines that provide therapeutic plasma exchange along with protocols aiming to support longevity and specially trained nurses to operate the devices. The goal is to deliver a circulatory-system tune up that cleans out inflammatory factors and biological compounds associated with aging. The machine removes a patient's blood, separates out the liquid plasma, and returns clean blood cells with a replacement protein fluid.
'The first step is to get [plasma exchange] out there and really be the first outpatient option for what I consider the coming renaissance of plasma exchange — the idea of targeted blood cleaning,' said Dr. Brad Younggren, Circulate's co-founder and CEO.
Since May 2024, Circulate has provided more than 1,000 treatments, which run about $8,000-$10,000 for a single session. The procedure is not proven to slow aging or covered by insurance.
Brad Younggren, CEO and co-founder of Circulate Health. (Circulate Photo)
Plasma exchange is considered medically effective for conditions including certain cases of multiple sclerosis and leukemia, Guillain Barre syndrome, sickle cell disease, some organ transplant situations, and other specific conditions.
The treatment is more recently being pitched as the next big thing by some promoters of biohacking — a lifestyle that includes using cutting-edge and not necessarily scientifically verified strategies for improving mental performance and longevity.
Circulate operated in stealth mode for a couple of years and officially launched in January 2024 when Younggren came on board. Its co-founder is Dr. Eric Verdin, CEO of the Buck Institute of Research on Aging in Novato California. Verdin's research is the scientific basis of Circulate's services.
The company partnered with the Buck Institute to research the impacts of plasma exchange and in May published a study in the journal Aging Cell.
The experiment looked at numerous age-related biomarkers found in cells that can be used to calculate someone's 'biological age.' It compared three groups of participants who were nearly 67 years old on average: one that received a placebo, one that received six plasma exchanges, and one that received six exchanges that included a dose of antibodies. The group receiving exchanges with antibodies fared the best, with a biological age reduction of 2.61 years on average.
'We saw a lot of expected outcomes that would be consistent with cellular rejuvenation,' Younggren said.
Study limitations
But the encouraging results come with significant caveats. Circulate's study was small and did not look for impacts that extended beyond the three to five months of treatments. The research also didn't measure changes to how a patient felt or test their cognitive health.
In a May article about the study in the New York Times, multiple medical experts questioned the significance of the findings.
Dr. Jeffrey Winters, chair of transfusion medicine at the Mayo Clinic, said the results don't indicate the therapy will lead to longer, healthier lives, telling the Times that the proof of longevity benefits 'really isn't there.'
Critics also noted that the last of the three blood samples taken during the study found reduced improvements compared to earlier samples, suggesting the benefits could wane over time. And there are safety concerns around the risk of infections or other complications with the treatment, which takes about two hours.
Most of the startup's partners are longevity clinics whose services can include: full-body MRIs used to look for early signs of cancer or other issues; genomic sequencing; more detailed blood analysis than is routinely performed by medical providers; and imaging of coronary arteries.
Younggren acknowledged that further research into the impacts of plasma exchange is warranted, and said the company is analyzing data routinely collected at the clinics as another source of insight.
People without thousands of dollars to spend on elective services can sell or donate their plasma for use in lifesaving medical treatments — and gain some of the potential benefits of the commercial treatment.
Younggren highlighted differences with Circulate's protocol that try to boost the longevity impacts. Circulate removes a larger volume of plasma and replaces it with a protein solution called albumin instead of the saline provided in donations. The startup also gives a dose of an antibody that could aid in 'cellular rejuvenation,' he said.
While longevity care in general is expensive, Younggren suggested that the economic — not to mention personal — benefits of preventing costly disease could pencil out at some point.
Circulate Health uses devices from Optia to provide plasma exchange. (Circulate Photo)
Longing for longevity
Younggren has worked for decades in medicine, serving as chief medical officer at Seattle telehealth startup 98point6 for seven years. He recruited Robbie Schwietzer, the former chief product officer at 98point6 and past operating partner with Khosla Ventures, to the Circulate team as chief operations officer.
Khosla was the lead investor in the newly announced seed round, which helped pay for the study published in Aging Cell. Seaside Ventures and CSC Ventures also invested.
Circulate's U.S. competitors include MaxWell Clinic and Next Health, which also provide plasma exchange to promote longer life.
Longevity tech is an evolving sector that attracted $1.8 billion in investments from 2021 through the first quarter of this year, according to PitchBook. While the field's focus was once on age-related ailments such as cardiovascular and neurological diseases, it's turning to biological factors associated with aging and extending lifespans, PitchBook noted.
Big names in tech such as Jeff Bezos and OpenAI's Sam Altman are backing health longevity startups. The Trump administration includes proponents such as Robert F. Kennedy Jr., the Secretary of Health and Human Services, who said he follows an anti-aging protocol and is promoting a 'make American healthy again' initiative.
Younggren said the startup could possibly apply for U.S. government funding to support research.
'This notion of making America healthy again,' Younggren said, 'fits right in with what we're trying to do.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
16-07-2025
- CNET
Ziploc, Rubbermaid Sued Over Microplastics: Should You Ditch Plastic Containers?
When you buy plastic food containers, you tend to look for whether they're microwave and freezer-safe. The maker of Rubbermaid, Newell Brands, is now facing a class action lawsuit for claiming that its plastic-based containers are "microwave safe" and "freezer-safe." According to the complaint, these products can release microplastics into food even when used as per the instructions, despite the products' marketing claiming otherwise. Ziploc is also facing a similar class action lawsuit. Ziploc storage bags contain polyethylene and polypropylene -- plastics known to release microplastics into foods when they're subject to extreme temperatures. Ziploc's packaging does not include a disclaimer for this. Brad Younggren of Circulate Health said, "Repeated exposure to extreme temperatures -- cold or hot -- stresses plastic materials and can lead to the breakdown of their surface layers, releasing tiny plastic particles into food." Microwaving food in plastic leads to the heat accelerating the amount of microplastics leaching into the food. "Similarly, freezing and thawing cycles can cause structural degradation that also encourages microplastic release, not unlike how freezing temperatures crack pavement in winter," Younggren said. Millions of families have been exposed to ingesting microplastics because of this misrepresentation of plastic products and the lack of disclosure. Reddit is full of threads about users concerned about being exposed to microplastics, with many debating whether plastic containers are safe. An estimate says that an average person intakes between 39,000 and 52,000 microplastic particles each year. If you account for airborne particles, that number jumps to 120,000. As of now, there's no established measure for what constitutes a "safe" or "unsafe" level of microplastic consumption, which is why it's important to understand where microplastics come from and how to reduce your intake. What's the deal with microplastics? Microplastics have long been a topic of conversation, mainly because they're important environmental pollutants. But these tiny plastic fragments don't just negatively impact the earth; they have potentially health impacts, too. Some days, it feels like we're regularly discovering a surprisingly high amount of microplastics lurking in our bodies. Scientists recently found high concentrations of microplastics in the brains of cadavers. While the US Food & Drug administration says scientific evidence doesn't suggest that the amount of microplastics in foods is a risk to our health, not all doctors are convinced. Microplastics located in the blood vessels have been linked to a higher risk of heart attack and stroke. Research has also found tissue inflammation, cell death and lung and liver impacts because of microplastics. That said, there's still plenty we don't know about the effects of microplastics. What we do know is that microplastics are everywhere. They're in the burned-down plastic spoon you should have thrown away years ago or the plastic-wrapped foods at the grocery store. However, it's not just how we package our foods. Microplastics can enter our food through soil and water contamination where they're grown. Since microplastics touch so many areas of our lives (did I mention they're also in the synthetic fibers of our clothing?), it can feel challenging to outrun them completely. While there's no established safe or unsafe level of microplastic consumption, most of us want to minimize our contact with them as much as possible. How can I limit my microplastic intake? This news doesn't automatically mean that plastic storage containers aren't safe to use. They remain one of the most affordable and convenient options for many families. However, it's not a bad idea to avoid freezing and microwaving them in the future. If you want to limit your family's consumption of microplastics even further, it's best to minimize your use of plastic in the kitchen. Remember, microplastics aren't just in plastic bags or containers. Top places microplastics lurk in your kitchen: Nonstick cookware Plastic cooking utensils Tea bags Plastic straws Canned food lining Plastic cutting boards So you should probably stop using Ziploc bags to freeze and microwave your food. But where does that leave you? Younggren suggested opting for non-plastic alternatives when you can. "We recommend microwave-safe glass containers as safer options," Younggren said. Glass containers are more stable under temperature stress, so the risk of microplastic contamination is lower. There are things you can do beyond changing how you store your food. You can opt for wood cutting boards instead of plastic, or use loose tea leaves or cook in cast iron. You'd probably be surprised by how much plastic is in your kitchen. A good rule of thumb when cooking is to note how often your food comes into contact with plastic. It's difficult to cut it entirely out of your life, though any strides you can make will reduce your microplastic intake.
Geek Wire
01-07-2025
- Geek Wire
Seattle startup Circulate Health raises $12M for pricey ‘blood-cleaning' longevity service
A patient receiving therapeutic plasma exchange services from Circulate Health. (Circulate Photo) Circulate Health, a Seattle health longevity startup, today announced $12 million in seed funding. The company is partnering with two-dozen clinics in eight states to provide a blood-cleaning service for patients in pursuit of longer, healthier lives. It recently published a study of 42 adults showing potential benefits following repeated treatments. Circulate is deploying machines that provide therapeutic plasma exchange along with protocols aiming to support longevity and specially trained nurses to operate the devices. The goal is to deliver a circulatory-system tune up that cleans out inflammatory factors and biological compounds associated with aging. The machine removes a patient's blood, separates out the liquid plasma, and returns clean blood cells with a replacement protein fluid. 'The first step is to get [plasma exchange] out there and really be the first outpatient option for what I consider the coming renaissance of plasma exchange — the idea of targeted blood cleaning,' said Dr. Brad Younggren, Circulate's co-founder and CEO. Since May 2024, Circulate has provided more than 1,000 treatments, which run about $8,000-$10,000 for a single session. The procedure is not proven to slow aging or covered by insurance. Brad Younggren, CEO and co-founder of Circulate Health. (Circulate Photo) Plasma exchange is considered medically effective for conditions including certain cases of multiple sclerosis and leukemia, Guillain Barre syndrome, sickle cell disease, some organ transplant situations, and other specific conditions. The treatment is more recently being pitched as the next big thing by some promoters of biohacking — a lifestyle that includes using cutting-edge and not necessarily scientifically verified strategies for improving mental performance and longevity. Circulate operated in stealth mode for a couple of years and officially launched in January 2024 when Younggren came on board. Its co-founder is Dr. Eric Verdin, CEO of the Buck Institute of Research on Aging in Novato California. Verdin's research is the scientific basis of Circulate's services. The company partnered with the Buck Institute to research the impacts of plasma exchange and in May published a study in the journal Aging Cell. The experiment looked at numerous age-related biomarkers found in cells that can be used to calculate someone's 'biological age.' It compared three groups of participants who were nearly 67 years old on average: one that received a placebo, one that received six plasma exchanges, and one that received six exchanges that included a dose of antibodies. The group receiving exchanges with antibodies fared the best, with a biological age reduction of 2.61 years on average. 'We saw a lot of expected outcomes that would be consistent with cellular rejuvenation,' Younggren said. Study limitations But the encouraging results come with significant caveats. Circulate's study was small and did not look for impacts that extended beyond the three to five months of treatments. The research also didn't measure changes to how a patient felt or test their cognitive health. In a May article about the study in the New York Times, multiple medical experts questioned the significance of the findings. Dr. Jeffrey Winters, chair of transfusion medicine at the Mayo Clinic, said the results don't indicate the therapy will lead to longer, healthier lives, telling the Times that the proof of longevity benefits 'really isn't there.' Critics also noted that the last of the three blood samples taken during the study found reduced improvements compared to earlier samples, suggesting the benefits could wane over time. And there are safety concerns around the risk of infections or other complications with the treatment, which takes about two hours. Most of the startup's partners are longevity clinics whose services can include: full-body MRIs used to look for early signs of cancer or other issues; genomic sequencing; more detailed blood analysis than is routinely performed by medical providers; and imaging of coronary arteries. Younggren acknowledged that further research into the impacts of plasma exchange is warranted, and said the company is analyzing data routinely collected at the clinics as another source of insight. People without thousands of dollars to spend on elective services can sell or donate their plasma for use in lifesaving medical treatments — and gain some of the potential benefits of the commercial treatment. Younggren highlighted differences with Circulate's protocol that try to boost the longevity impacts. Circulate removes a larger volume of plasma and replaces it with a protein solution called albumin instead of the saline provided in donations. The startup also gives a dose of an antibody that could aid in 'cellular rejuvenation,' he said. While longevity care in general is expensive, Younggren suggested that the economic — not to mention personal — benefits of preventing costly disease could pencil out at some point. Circulate Health uses devices from Optia to provide plasma exchange. (Circulate Photo) Longing for longevity Younggren has worked for decades in medicine, serving as chief medical officer at Seattle telehealth startup 98point6 for seven years. He recruited Robbie Schwietzer, the former chief product officer at 98point6 and past operating partner with Khosla Ventures, to the Circulate team as chief operations officer. Khosla was the lead investor in the newly announced seed round, which helped pay for the study published in Aging Cell. Seaside Ventures and CSC Ventures also invested. Circulate's U.S. competitors include MaxWell Clinic and Next Health, which also provide plasma exchange to promote longer life. Longevity tech is an evolving sector that attracted $1.8 billion in investments from 2021 through the first quarter of this year, according to PitchBook. While the field's focus was once on age-related ailments such as cardiovascular and neurological diseases, it's turning to biological factors associated with aging and extending lifespans, PitchBook noted. Big names in tech such as Jeff Bezos and OpenAI's Sam Altman are backing health longevity startups. The Trump administration includes proponents such as Robert F. Kennedy Jr., the Secretary of Health and Human Services, who said he follows an anti-aging protocol and is promoting a 'make American healthy again' initiative. Younggren said the startup could possibly apply for U.S. government funding to support research. 'This notion of making America healthy again,' Younggren said, 'fits right in with what we're trying to do.'
Associated Press
28-05-2025
- Associated Press
Circulate Health Publishes Results of Multiomics Study Demonstrating Impact of Therapeutic Plasma Exchange on Biological Age in Aging Cell
First-of-its kind trial shows that therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as measured by multi-omics biomarkers NOVATO, Calif., May 28, 2025 /PRNewswire/ -- Circulate Health, the company dedicated to harnessing the potential of therapeutic plasma exchange (TPE) to advance human healthspan and lifespan, today announces the publication of a single blind, human clinical trial in Aging Cell. This groundbreaking study, led by researchers from Circulate and the Buck Institute for Research on Aging provides promising early data on the impact of TPE on biological age, supporting its potential for new disease and longevity applications. 'Unfortunately, most so-called 'longevity interventions' lack proven effectiveness in humans. By conducting clinical trials, we aim to change that—this study marks the first step in demonstrating that plasma exchange can significantly improve key mechanisms of biological aging,' commented Dr. David Furman, senior author of the Aging Cell paper. Therapeutic plasma exchange is a procedure that separates, removes, and replaces patient plasma to treat certain diseases. Multi-omics Analysis Reveals Biomarkers that Contribute to Biological Age Rejuvenation in Response to Therapeutic Plasma Exchange, investigated how TPE impacts biomarkers associated with biological age, including changes across the epigenome, proteome, metabolome, glycome, and immune system, alongside physical measures like balance and strength. Research participants were assigned one of four different treatment groups: 1) biweekly TPE, 2) biweekly TPE with intravenous immunoglobulin (IVIG) 3) monthly TPE or 4) a control group. The study found: 'This is the first interventional multi-omics study to examine the effectiveness of therapeutic plasma exchange modalities,' said Brad Younggren, MD, CEO and Co-founder of Circulate. 'Our findings show that plasma exchange and intravenous immunoglobulin are a powerful tool for biological age rejuvenation and provide compelling evidence that targeted plasma interventions can impact age-related molecular changes.' 'In this study, we examined thousands of molecular signatures to pinpoint key drivers of rejuvenation. Our characterization builds a better understanding of which baseline biomarkers are predictive of treatment response and lays a foundation upon which we can build personalized intervention plans for patients in the future,' said Eric Verdin, MD, President and CEO of the Buck Institute and Co-founder of Circulate. 'We are excited to expand our research to larger populations, increase access to these treatments for eligible patients, and continue to identify areas of unmet need where these therapies can make a meaningful difference.' Clinicians can learn more about Circulate at About Circulate Health Backed by Khosla Ventures, Circulate Health is pioneering technologies to reverse aging and improve health outcomes. About Buck Institute Our success will ultimately change healthcare. At the Buck, we aim to end the threat of age-related diseases for this and future generations by bringing together the most capable and passionate scientists from a broad range of disciplines to identify and impede the ways in which we age. An independent, nonprofit institution, our goal is to increase human healthspan, or the healthy years of life. Globally recognized as the pioneer and leader in efforts to target aging, the number one risk factor serious diseases including Alzheimer's, Parkinson's, cancer, macular degeneration, heart disease, and diabetes, the Buck wants to help people live better longer. Learn more at: View original content: SOURCE Circulate Health
